THERAPEUTIC PROCEDURES THAT REQUIRE
LARGE BORE VENOUS ACCESS CLOSURE
Current Trans-Venous Procedures
Current therapies that require large bore venous vascular access:
- ASD Closure
- Left Arterial Appendix Occluder
- Mitral Valve Repair (currently only one technology available)
- Vena Cava Filter
- Atrial Ablation
- Pulmonary Embolectomy
- Venous Thrombectomy
These trans-venous therapies add up to approximately 5 million procedures per year in USA and Europe.
Upcoming Trans-Venous Procedures
A dramatic increase in interventional procedures that require large bore venous vascular access site is expected once novel technologies under development for structural heart treatment in development will mature.
- Transcatheter Mitral Valve Repair
- Transcatheter Mitral Valve Prosthesis Implantation
- Transcatheter Tricuspid Valve Repair
- Transcatheter Tricuspid Valve Prosthesis Implantation
- Intra-Atrial Shunt Therapy
- Left Ventricle Restoration
- Left Ventricle Volume Reduction
- Right Ventricle Assist Devices
As soon as these procedures are fully developed and utilized, the market for large bore venous access closure is expected to grow to 30 million procedures per year in the USA and Europe.
As of today there exists no effective vascular closure device for large bore punctures of venous vessels in the clinical practice.
The Venock System
The Venock vascular closure device is a percutaneous hand held device for automated closure of a large bore puncture in the femoral vein following an interventional procedure. The device is inserted over the already positioned guidewire in the vein and the perforation is tightly sealed within 1-2 minutes procedure time.
Advantages of Venock Vascular Closure Device
Hospitals and MedTech Device Developers
Abstract of the White Paper
The Venock device offers benefits for many different stakeholders. In addition to improving patient comfort, the Venock device aids in the general acceptance of large bore transcatheter interventions, which benefits device developers and, of course, hospitals and clinics.
The Venock device allows for more efficient cathlab capacity utilization and higher patient turnover, while drastically reducing cost and recovery time. Cathlabs are determined to find ways to save resources and increase patient turnover in order to make transcatheter procedures more profitable.
Although cathlab resources are limited, it is in the chief interest of global MedTech companies to streamline cathlab procedures in order to increase the number of procedures per day. The Venock vascular closure device is such a device that will drastically reduce patient length of stay and use of resources, while allowing for higher patient turnover, faster mobilization, and earlier discharge.
DR. SAMEER GAFOOR
Large-bore femoral venous access is becoming more commonplace, but access closure still often requires hours of postprocedural monitoring and bedrest.
I am happy to hear that Venock is developing a large bore venous closure that facilitate early hospital discharge for this fast-growing patient population.
STRUCTURAL HEART DISEASE SWEDISH MEDICAL CENTER, SEATTLE, WA, USA
PROF. DR. CHRISTIAN HENGSTENBERG
Large bore venous closure has long been a drain on time and resources during many of my procedures. I am thrilled to hear that Venock is taking on this important task and am convinced their approach will produce a robust and effective device that is closing large bore venous punctures within minutes.
My patients tell me that their only negative memory after an interventional procedure is being bedridden with a compression bandage and suffering from a hematoma and considerable pain in their groin. I am eager to provide a solution which will end this pain.
DIRECTOR UNIVERSITY HOSPITAL VIENNA, AUSTRIA
PROF. DR. HORST SIEVERT
Arterial closure devices have tremendously improved the post-interventional recovery process by saving time and resources, decreasing patient discomfort, and eliminating complications like hematoma. I am looking forward to seeing the same benefits in large bore venous closure.
The Venock device will attain large bore venous closure in under a minute, thus saving time and money, while significantly reducing patient discomfort and time to discharge when compared to the recovery from manual compression.
DIRECTOR OF CENTER FOR CARDIOLOGY, PERIPHERAL VASCULAR AND CEREBROVASCULAR DISEASE FRANKFURT, GERMANY
CARLOS E. RUIZ, MD, PhD, FACC, FESC, MSCAI
I think extended external groin compression in patients undergoing cardiovascular interventions is by far, one of the most common dreadful memories that patients have afterwards. We have done major steps in avoiding this when we do arterial access using a multitude of closing devices. The problem is now more prominent with the increasing use of large-bore venous access for a multitude of new procedures. The Venock device will be the next step solution to improve further patient satisfaction
FORMER DIRECTOR STRUCTURAL HEART, LENOX HILL HEART AND VASCULAR INSTITUTE, NEW YORK, USA
Our Management Team
Powered by People
CHIEF EXECUTIVE OFFICER
Dipl.-Kfm. Marcus Irsfeld
CHIEF FINANCIAL OFFICER
Dr. Wolfgang Goetz
FOUNDER & CHAIRMAN OF THE BOARD
Get in Touch
HEAD QUARTER USA
521 Fifth Avenue, Floor 17 | New York, NY 10175 | USA
VENOCK MEDICAL GMBH
c/o WeWork | Neuturmstrasse 5 | 80331 München | Germany
MEETING US AT EVENTS
We plan to attend the following events and are looking forward to arranging a meeting with you.
Are you interested in an investment or in a joint development?
Please contact us.
Förderprogramm WIPANO des Bundesministeriums für Wirtschaft und Energie
External link: http://www.wipano.de